Shionogi to Modernize Product Quality Management in the Cloud with Veeva Vault QMS

Pharmaceutical company in Japan unifies product quality management processes across global stakeholders

Veeva Systems today announced that Shionogi & Co., Ltd., a company in Japan, decided to select Veeva Vault QMS to improve the efficiency of product quality management across its sites inside and outside Japan. With Vault QMS, Shionogi will modernize its global product quality management processes.

Shionogi required greater simplicity and flexibility in managing its product quality management processes. The fast implementation and user-friendly configuration environment of Vault QMS are expected to provide greater agility in addressing changing business and regulatory requirements. In addition, Vault QMS is expected to help Shionogi drive seamless information management for external stakeholders with an innovative, cloud-based application.

"Shionogi is committed to continuous innovation in everything they do," said Takashi Okamura, general manager of Veeva Japan. "We're honored that they have chosen Veeva Vault QMS to harmonize their global product quality management processes."

Veeva Vault QMS is a modern, cloud-based application that unifies quality management processes and internal and external stakeholders for better control and visibility. This will contribute to reducing risks related to the product quality of medicines and continuously providing patients worldwide with high-quality medicines.

Additional Information

For more on Veeva Vault QMS, visit: veeva.com/QMS

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veevasystems on Twitter: twitter.com/veevasystems

Like Veeva on Facebook: facebook.com/veevasystems

About Shionogi

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and wellbeing of the patients we serve." Shionogi's research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders. For over 50 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives. Contributing to the health and quality of life of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp/en/.

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 600 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2017. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180326005275/en/